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typically negative for most or all mesothelioma markers. The most 
useful differential diagnostic feature is the gross distribution of tumor 
as determined by radiographic studies. The ﬁnding of a mass lesion 
in the lung with extension to the pleura or chest wall should be a “red 
ﬂag” for the surgical pathologist contemplating a diagnosis of sarcoma-
toid mesothelioma. This is especially true for an apical lesion, where 
constraints dictated by the anatomy make the likelihood for pleural 
invasion by a sarcomatoid carcinoma quite high.
Paucicellular collagenous lesions
Fibrotic lesions involving the pleura invoke the differential diagnosis of 
ﬁbrous pleurisy versus desmoplastic mesothelioma. Fibrous pleurisy is 
typically a rather uniform process lacking nodularity. Fibrous pleurisy 
tends to show zonation, with the most cellular aspects of the lesion 
located near the pleural surface. In addition, one may observe capillar-
ies perpendicular to the surface traversing the thickness of the pleural 
lesion. Mitotic activity is of little beneﬁt in the differential diagnosis. 
Furthermore, the ﬁnding of keratin positive spindle cells does not help, 
since both ﬁbrous pleurisy and desmoplastic mesothelioma may display 
this feature.2
A diagnosis of desmoplastic malignant mesothelioma can be made 
when a ﬁbrous pleural lesion demonstrates one or more of the fol-
lowing characteristics: 1) frankly sarcomatoid areas, 2) foci of bland 
necrosis, 3) invasion of lung or chest wall, and 4) distant metastases.7 
Invasion may be more easily demonstrated by means of keratin im-
munostaining. The ﬁnding of keratin positive spindle cells insinuating 
between chest wall adipocytes is a particularly useful feature. Expansile 
pleural nodules are also a useful ﬁnding. Extensive sampling may be 
necessary to demonstrate the diagnostic features of malignancy.
Mixed or biphasic lesions
Although a pleural-based lesion with a biphasic histological pattern 
usually suggests a diagnosis of mesothelioma, other diagnostic pos-
sibilities must also be entertained.8 These include spindle cell carcino-
mas, carcinosarcomas, biphasic synovial sarcomas, and rare cases of 
epithelioid hemangioendothelioma. Biphasic mesotheliomas tend to be 
less differentiated than epithelial mesotheliomas, so staining for some 
mesothelial markers may be lost in the epithelial component. The same 
is true for spindle cell carcinomas and carcinosarcomas, which may fail 
to stain for the usual carcinoma markers. For biphasic pleural tumors, 
we use as positive markers broad-spectrum cytokeratins, calretinin, 
cytokeratins 5/6, WT-1 and D2-40, and as negative markers, CEA and 
TTF-1. The panel for biphasic peritoneal tumors is the same, except 
that we substitute BerEP4 and B72.3 for CEA and TTF-1.5 It should 
be noted that the epithelial component of biphasic synovial sarcoma is 
often positive for calretinin. Distinguishing features include positive 
staining for BerEP4 and negative staining for WT-1. In addition, bipha-
sic synovial sarcomas may stain positive with PASD and demonstrate 
the characteristic fusion transcript by RT-PCR or FISH.
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Surgery for mesothelioma is feasible now at more centers and has 
a lower morbidity and mortality than previously reported. Surgery, 
however, is only part of the treatment package for the disease, and can 
be combined with preoperative, intraoperative, and postoperative thera-
pies. The following is an overview of this concept. 
Staging and operative therapy
Patients are candidates for surgical resection in mesothelioma if a cyto-
reductive procedure can be performed that does not leave gross disease 
at its completion, or, in other words, leaves only microscopic residual 
disease. When enlarged mediastinal lymph nodes are detected by CT or 
PET scan, a mediastinoscopy should be performed. 
Which Operation?
The role of surgery in mesothelioma, as well as what type of surgery 
remains extraordinarily controversial since there is a lack of ran-
domized controlled clinical trials making it impossible to determine 
whether the use of extrapleural pneumonectomy (EPP) or pleurectomy 
(PL) improves survival or effectively palliates the symptoms of the 
disease. There is no doubt that EPP is a more extensive dissection 
and may serve to remove more bulk disease than a PL, chieﬂy in the 
diaphragmatic and visceral pleural surfaces. Some surgeons, however, 
include diaphragmatic resection and pericardial resection with their 
PLs to accomplish removal of “all gross disease.” Recent data from 
Flores and Pass in a series of more than 600 patients having PL or EPP 
for pleural mesothelioma revealed that PL may be just as efﬁcacious as 
EPP for early stage mesothelioma.
Lymph node status has emerged as one of the most important prognos-
tic indicators for patients having EPP. Retrospective data from selected 
small series suggest that for patients with nodal positivity, PL had a 
median survival of 16 months while EPP was 15 months. 
Due to its magnitude, EPP has signiﬁcantly greater morbidity than PL. 
The major complication rate ranges from 20% to 40%, and arrhyth-
mia requiring medical management is the most common complica-
tion, however, Rusch reported a perioperative mortality of 6% to 8% 
after EPP, and Sugarbaker et al. reported a benchmark perioperative 
mortality of 3.4%. Mortalities were due to myocardial infarction and 
presumed pulmonary emboli. 
EPP is associated with distant sites of recurrence compared to locore-
gional sites of recurrence in patients having biopsy only or pleurec-
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tomy-decortication, and the local control for EPP is superior to that of 
the other modalities. 
Surgery And Multimodality Therapies
Combined Surgical Resection and Deﬁnitive Radiotherapy
After an EPP, radical radiotherapy can be administered without con-
cern for damage to the underlying ipsilateral lung because it has been 
removed surgically. However, radical radiotherapy after a pleurectomy 
continues to place the ipsilateral lung at risk for substantial loss of 
function. In a retrospective review of patients having P/D at Memorial 
Sloan-Kettering Cancer Center from 1974 to 2003 the data revealed that 
residual disease cannot be eradicated with external RT with or without 
brachytherapy and that a more extensive surgery followed by external 
RT might be required to improve local control and overall survival. 
Radiation therapy after EPP however, is beneﬁcial. Rusch completed a 
phase II trial of surgery followed by postoperative radiation in patients 
with pleural mesothelioma having EPP. The median survival was 17 
months, with an overall survival of 27% at 3 years. Only 13% had 
locoregional recurrence, with the majority of patients failing to respond 
and having distant metastases. 
IMRT also offers the potential for administering higher doses of radio-
therapy to the hemithorax while minimizing normal tissue toxicities. 
Recent data in 63 patients having EPP and IMRT reveals a median 
survival of 15 months for all patients, with patients having N0 status 
improving to 20 months compared to those with N1/N2 disease being 
11 months. Six patients experienced pulmonary complications leading 
to death which was attributable to the IMRT, usually at higher doses. 
These pulmonary complications have also been documented from the 
Dana Farber Cancer Institute. 
Pleurectomy/Intrapleural Chemotherapy ± Postoperative Chemo-
therapy
There has been interest in combining debulking surgery with intra-
cavitary treatment of pleural mesothelioma since the ﬁrst reports of 
intrapleural chemotherapy alone for malignant mesothelioma. The most 
recent trials of surgery and intrapleural chemotherapy have revealed an 
overall survival rate of 68% at 1 year and 44% at 2 years in the 27 pa-
tients who received the therapy, with a median survival of 17 months. 
Recurrences are chieﬂy locoregional. 
Extrapleural Pneumonectomy/Intravenous Chemotherapy and Postop-
erative Radiotherapy
A multimodal approach to malignant mesothelioma using EPP, postop-
erative chemotherapy, and targeted postoperative radiotherapy was the 
standard approach since 1980 at the Brigham and Women’s Hospital in 
Boston. Over a 19-year period, 183 patients have been treated with a 
perioperative mortality of 3.4%. The median survival in this group of 
patients is approximately 17 months, which was a signiﬁcant improve-
ment over other trials. This approach by the Boston Group has now 
been generally replaced with novel trials of intrapleural hyperthermic 
perfusion. 
Induction Chemotherapy followed by Surgery
With the improved efﬁcacy of doublet chemotherapy (gemcitabine/cis-
platin or pemetrexed/cisplatin), there is renewed interest in investigat-
ing a neoadjuvant approach for mesothelioma. A Swiss neoadjuvant 
study used three cycles of cisplatin and gemcitabine followed by EPP 
and RT to areas at risk. Of the 37 patients who had complete resec-
tion 36 received postoperative radiotherapy, and the mortality was 2%. 
Postoperative complications were observed in 62% and 2 patients died 
within 30 days (3.2%). For all patients, the one year survival was 69% 
with median survival of 18.4 months. For the 45 resected patients, 78% 
were alive at one year with a median survival of 26.3 months. Prelimi-
nary results of a multicenter North American trial of four cycles of 
pemetrexed and cisplatin followed by EPP and postoperative hemitho-
rax RT were presented at ASCO 2007. Of 77 patients initially enrolled, 
four cycles of chemotherapy could be delivered to 83% , but only 54/77 
had surgical exploration of which 47 had an EPP. Of these 47, 35 com-
pleted RT. Operative morality was 4%, and 1 year survival was 68%, 
with median survival of 16 months. 
Novel Intrapleural Approaches: New Techniques with New/Old Agents 
– Intrapleural Photodynamic Therapy
Photodynamic therapy (PDT) involves the light-activated sensitization 
of malignant cells using a photosensitizer, such as Photofrin II, which is 
retained by malignant tissue in vivo in comparison to normal tissue. Af-
ter a series of phase I and II trials, a group of 63 patients with localized 
mesothelioma were randomized to surgery, with or without intraopera-
tive PDT . There were no differences in median survival (14.4 vs. 14.1 
months) or median progression-free time (8.5 vs. 7.7 months), and 
sites of ﬁrst recurrence were similar. Other phase II trials of PDT and 
mesothelioma have not demonstrated limited therapeutic efﬁcacy, and 
results using intrapleural PDT with metaTetraHydroxyPhenylChlorin 
after EPP have revealed signiﬁcant toxicities without survival beneﬁt.
Pleural Perfusion
Hyperthermic chemoperfusion of the pleura after resection of meso-
thelioma is based on the hypothesis that the treatment will provide 
increased local control and avoid systemic chemotherapy toxicity. 
Sugarbaker has reported a phase I/II trial using hyperthermic cisplatin 
(42°C) to perfuse both the abdomen and the pleura after pleurec-
tomy/decortication. Operative mortality was 11%, and survival of all 
patients was 10.5 months; however, in the group of patients surviving 
surgery who received 225 mg/m2 of cisplatin, the median survival was 
22 months, and disease-free survival was 20 months. Further data with 
hyperthermic perfusion in patients having EPP are forthcoming. 
Conclusions
Despite safer surgery and new systemic therapies, median survival for 
mesothelioma patients having multimodality therapy is approximately 
24 months. Only through earlier recognition of the disease and discov-
ery of novel targets which will have satisfactory toxicity proﬁles can 
these median survivals be improved. 
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The incidence of malignant pleural mesothelioma (MPM) is increasing 
in many countries, and is expected to continue to rise for at least the 
next decade. The impacts of the disease include shortened life expec-
tancy, symptoms, and impairment of quality of life. For patients with 
early disease, aggressive multimodality therapy may improve out-
comes. However, the majority of patients who develop mesothelioma 
are not candidates for this type of approach, and will ultimately die of 
their disease. Therefore effective palliative treatments are required that 
can increase life span, minimize symptoms and improve quality of life. 
This presentation will focus on the development of systemic therapies 
for mesothelioma.
